Private Markets, Angel and Secondary Investing, Sacra

Sacra

Bringing transparency to private markets so investors, founders, and employees can build on conviction.

Sacra delivers deeply researched insights on the private companies shaping tomorrow's markets. By surfacing the data, context, and operator perspective that are missing from private markets today, we help secondary buyers and sellers price equity accurately and unlock liquidity for the people building these businesses.

Private Markets, Angel and Secondary Investing

Bringing transparency to private markets so investors, founders, and employees can build on conviction. Sacra delivers deeply researched insights on the private companies shaping tomorrow's markets. By surfacing the data, context, and operator perspective that are missing from private markets today, we help secondary buyers and sellers price equity accurately and unlock liquidity for the people building these businesses.

Private Capital Markets

<ul><li>Virta Health (2014) is a telehealth provider that sells type 2 diabetes reversal via the ketogenic diet as a benefit ($2.8K per patient with a $10-20K platform fee per year) into health plans and self-insured employers, delivering it through a combo of connected devices (glucose meter, ketone meter, scale), 2-4 daily health coach check-ins, and continuous physician oversight.</li><li>In 2022, Virta launched a second product for obesity ($900/year), with Sacra now estimating Virta will do $175M of revenue in 2024, up 51% YoY, with roughly 550 customers (~$318K ARPC) and 98,000 patients (~180 patients per customer) for blended average revenue per patient of $1.8K.</li><li>With Ozempic’s runaway success ($14B of sales in 2023) driving up employer health costs by ~10% YoY, Virta’s obesity product (growing 150% YoY) provides a cheaper, pharma-free alternative ($900/year vs. $3,000/year), with new employer signups for obesity now growing faster than their diabetes reversal product.</li></ul>

Virta Health (2014) is a telehealth provider that sells type 2 diabetes reversal via the ketogenic diet as a benefit ($2.8K per patient with a $10-20K platform fee per year) into health plans and self-insured employers, delivering it through a combo of connected devices (glucose meter, ketone meter, scale), 2-4 daily health coach check-ins, and continuous physician oversight.In 2022, Virta launched a second product for obesity ($900/year), with Sacra now estimating Virta will do $175M of revenue in 2024, up 51% YoY, with roughly 550 customers (~$318K ARPC) and 98,000 patients (~180 patients per customer) for blended average revenue per patient of $1.8K.With Ozempic’s runaway success ($14B of sales in 2023) driving up employer health costs by ~10% YoY, Virta’s obesity product (growing 150% YoY) provides a cheaper, pharma-free alternative ($900/year vs. $3,000/year), with new employer signups for obesity now growing faster than their diabetes reversal product.

Virta Health

Virta Health At $175M Revenue